Patients with BRCA1/2 germline mutated serous ovarian cancers responded better to first-line chemotherapy in the metastatic setting in comparison with sporadic serous high-grade carcinomas (Hennessy et al. 2010; Mafficini et al. 2016; Moschetta et al. 2016; Muggia 2009; Oza et al. 2015; Kwon et al. 2010; Muggia et al. 2011). The gene discussed is BRCA1; the disease is ovarian serous adenocarcinoma.